Skip to content
Reipet – Lifestyle
Author:
Edgewise Therapeutics
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
June 3, 2026
Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
June 1, 2026
Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up
March 10, 2026